Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
p53 tumor suppressor
is regulated by MDM2-mediated ubiquitination and degradation. Mitogenic signals activate
p53
by induction of ARF expression, which inhibits
p53
ubiquitination by MDM2. Recent studies showed that the MDM2 homolog
MDMX
is also an important regulator of
p53
. We present evidence that MDM2 promotes
MDMX
ubiquitination and degradation by the proteasomes. This effect is stimulated by ARF and correlates with the ability of ARF to bind MDM2. Promotion of MDM2-mediated
MDMX
ubiquitination requires the N-terminal domain of ARF, which normally inhibits MDM2 ubiquitination of
p53
. An intact RING domain of MDM2 is also required, both to interact with
MDMX
and to provide E3 ligase function. Increase of MDM2 and ARF levels by DNA damage, recombinant ARF adenovirus infection, or inducible MDM2 expression leads to proteasome-mediated down-regulation of
MDMX
levels. Therefore,
MDMX
and MDM2 are coordinately regulated by stress signals. The ARF tumor suppressor differentially regulates the ability of MDM2 to promote
p53
and
MDMX
ubiquitination and activates
p53
by targeting both members of the MDM2 family.
...
PMID:MDM2 promotes ubiquitination and degradation of MDMX. 1286 Sep 99
Although genetic studies have demonstrated that
MDMX
is essential to maintain
p53
activity at low levels in non-stressed cells, it is unknown whether
MDMX
regulates
p53
activation by DNA damage. We show here that DNA damage-induced
p53
induction is associated with rapid down-regulation of the
MDMX
protein. Significantly, interference with
MDMX
down-regulation results in the suppression of
p53
activation by genotoxic stress. We also demonstrate that DNA damage-induced
MDMX
reduction is mediated by MDM2, which targets
MDMX
for proteasomal degradation by a distinct mechanism that permits preferential
MDMX
degradation and therefore ensures optimal
p53
activation.
...
PMID:DNA damage-induced MDMX degradation is mediated by MDM2. 1296 17
The
p53 tumor suppressor
is a transcription factor that is activated by diverse genotoxic and cytotoxic stresses. Upon activation,
p53
prevents the proliferation of genetically unstable cells by regulating the expression of genes that initiate cell cycle arrest, apoptosis, and DNA repair. Consequently,
p53
must be kept inactive in unstressed cells as its inappropriate activation can cause premature senescence and death.
p53
inhibition occurs primarily through the E3 ubiquitin ligase, MDM2. Because MDM2 is also a p53 target gene, stresses paradoxically activate
p53
while simultaneously increasing MDM2 expression. Therefore, a challenge has been to explain how the abundant MDM2 is prevented from inhibiting
p53
, thus ensuring that
p53
can execute an appropriate stress response. Here we discuss a new mechanism for
p53
activation involving DNA damage-induced auto-degradation of MDM2. Our data reveal that DNA damage leads to the destabilization of MDM2, which correlates with
p53
stabilization and target gene induction. Conversely,
p53
levels and activity decrease when MDM2 returns to a more stable state later in the stress response. The destabilization of MDM2 is required for
p53
activation, as blocking MDM2 degradation via proteasome inhibition prevents
p53
transactivation in DNA-damaged cells by enabling MDM2 to bind and inhibit
p53
. MDM2 destabilization is controlled by DNA damage-activated post-translational modifications and by its own RING domain, implying a possible role for the RING domain-interacting protein,
MDMX
, in regulating MDM2 stability. We propose that accelerated degradation of MDM2 limits its binding to
p53
during a stress response and enables
p53
to accumulate and remain active, even as
p53
transcriptionally activates more MDM2. Thus, the induction of MDM2 RNA by activated
p53
may create a reserve of MDM2 that can inactivate
p53
once the DNA damage stimulus has abated and MDM2 is restabilized. As many tumors inactivate wild type
p53
through MDM2 overexpression, exploiting the pathways that trigger MDM2 auto-degradation may be an important new strategy for chemotherapeutic intervention.
...
PMID:A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. 1568 15
MDMX
is a homolog of MDM2 and is critical for regulating
p53
function during mouse development.
MDMX
level is regulated by MDM2-mediated poly-ubiquitination, which results in its accelerated degradation after DNA damage or expression of ARF. In this report, we demonstrate that
MDMX
can be modified by conjugation to SUMO-1 both in vivo and in vitro. We found that double mutation of two lysine residues, K254 and K379, abrogated
MDMX
sumoylation in vivo. Experiments using the sumoylation-deficient
MDMX
mutant showed that it undergoes normal ubiquitination and degradation by MDM2, normal nuclear translocation and degradation after DNA damage, and inhibits
p53
with wild type efficiency. Therefore, sumoylation is not required for several activities of
MDMX
under our assay conditions.
...
PMID:Modification of MDMX by sumoylation. 1590
MDMX
is a homolog of MDM2 that is critical for regulating
p53
function during mouse development.
MDMX
degradation is regulated by MDM2-mediated ubiquitination. Whether there are other mechanisms of
MDMX
regulation is largely unknown. We found that
MDMX
binds to the casein kinase 1 alpha isoform (CK1alpha) and is phosphorylated by CK1alpha. Expression of CK1alpha stimulates the ability of
MDMX
to bind to
p53
and inhibit
p53
transcriptional function. Regulation of
MDMX
-
p53
interaction requires CK1alpha binding to the central region of
MDMX
and phosphorylation of
MDMX
on serine 289. Inhibition of CK1alpha expression by isoform-specific small interfering RNA (siRNA) activates
p53
and further enhances
p53
activity after ionizing irradiation. CK1alpha siRNA also cooperates with DNA damage to induce apoptosis. These results suggest that CK1alpha is a functionally relevant
MDMX
-binding protein and plays an important role in regulating
p53
activity in the absence or presence of stress.
...
PMID:Regulation of p53-MDMX interaction by casein kinase 1 alpha. 1602 88
The E2F1 transcription factor can initiate proliferation or apoptosis, the latter by both transcription-dependent and -independent mechanisms. Recently, an E2F1 mutant lacking the DNA binding domain, E2F1(180-437), has been implicated in degradation of
MDMX
and MDM2 proteins via lysosomal proteases. MDM proteins block
p53
dependent apoptosis by directly inhibiting
p53
stability and function. Here we demonstrate E2F1(180-437) induces death in HEK293 cells independent of E2F1 transcriptional activation and
p53
stabilization. E2F1(180-437) elevates the activity of the calcium-activated protease, calpain, which is required for E2F1 induced proteolysis of
MDMX
and E2F1 induced cell loss. To determine if E2F1 could be activating proteolysis via calpains in neurodegeneration, we examined
MDMX
immunofluorescence in simian immunodeficiency virus encephalitis (SIVE). We found a reciprocal relationship between E2F1 and
MDMX
staining: in SIVE where E2F1 immunostaining is increased,
MDMX
is decreased, while in controls where E2F1 immunostaining is low,
MDMX
is high. Together these experiments support a new function for E2F1 in the activation of calpain proteases and suggest a role for this pathway in SIVE.
...
PMID:E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. 1608 44
The
p53 tumor suppressor
is activated after DNA damage to maintain genomic stability and prevent transformation. Rapid activation of
p53
by ionizing radiation is dependent on signaling by the ATM kinase. MDM2 and
MDMX
are important
p53
regulators and logical targets for stress signals. We found that DNA damage induces ATM-dependent phosphorylation and degradation of
MDMX
. Phosphorylated
MDMX
is selectively bound and degraded by MDM2 preceding
p53
accumulation and activation. Reduction of
MDMX
level by RNAi enhances
p53
response to DNA damage. Loss of ATM prevents
MDMX
degradation and
p53
stabilization after DNA damage. Phosphorylation of
MDMX
on S342, S367, and S403 were detected by mass spectrometric analysis, with the first two sites confirmed by phosphopeptide-specific antibodies. Mutation of
MDMX
on S342, S367, and S403 each confers partial resistance to MDM2-mediated ubiquitination and degradation. Phosphorylation of S342 and S367 in vivo require the Chk2 kinase. Chk2 also stimulates
MDMX
ubiquitination and degradation by MDM2. Therefore, the E3 ligase activity of MDM2 is redirected to
MDMX
after DNA damage and contributes to
p53
activation.
...
PMID:ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. 1616 88
The MDM2 homolog
MDMX
is an important regulator of
p53
during mouse embryonic development. DNA damage promotes
MDMX
phosphorylation, nuclear translocation, and degradation by MDM2. Here we show that
MDMX
copurifies with 14-3-3, and DNA damage stimulates
MDMX
binding to 14-3-3. Chk2-mediated phosphorylation of
MDMX
on S367 is important for stimulating 14-3-3 binding,
MDMX
nuclear import by a cryptic nuclear import signal, and degradation by MDM2. Mutation of
MDMX
S367 inhibits ubiquitination and degradation by MDM2, and prevents
MDMX
nuclear import. Expression of 14-3-3 stimulates the degradation of phosphorylated
MDMX
. Chk2 and 14-3-3 cooperatively stimulate
MDMX
ubiquitination and overcome the inhibition of
p53
by
MDMX
. These results suggest that
MDMX
-14-3-3 interaction plays a role in
p53
response to DNA damage by regulating
MDMX
localization and stability.
...
PMID:Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. 1651 60
It has been shown that
MDMX
inhibits the activity of the
tumor suppressor p53
by primarily cooperating with the
p53
feedback regulator MDM2. Here, our study shows that this inhibition can be overcome by 14-3-3gamma and Chk1. 14-3-3gamma was identified as an
MDMX
-associated protein via an immuno-affinity purification-coupled mass spectrometry. Consistently, 14-3-3gamma directly interacted with
MDMX
in vitro, and this interaction was stimulated by
MDMX
phosphorylation in vitro and in cells. Interestingly, in response to UV irradiation, the wild-type, but not the kinase-dead mutant, Chk1 phosphorylated
MDMX
at serine 367, enhanced the 14-3-3gamma-
MDMX
binding and the cytoplasmic retaining of
MDMX
. The Chk1 specific inhibitor UCN-01 repressed all of these effects. Moreover, overexpression of 14-3-3gamma, but not its mutant K50E, which did not bind to
MDMX
, suppressed
MDMX
-enhanced
p53
ubiquitination, leading to
p53
stabilization and activation. Finally, ablation of 14-3-3gamma by siRNA reduced UV-induced
p53
level and G1 arrest. Thus, these results demonstrate 14-3-3gamma and Chk1 as two novel regulators of
MDMX
in response to UV irradiation.
...
PMID:14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. 1651 72
The
p53 tumor suppressor
plays a key role in maintaining genomic stability and protection against malignant transformation. MDM2 and
MDMX
are both
p53
-binding proteins that regulate
p53
stability and activity. Recent development of the MDM2 inhibitor Nutlin 3 has greatly facilitated functional analysis of MDM2-
p53
binding. We found that although
MDMX
is homologous to MDM2 and binds to the same region on
p53
N terminus, Nutlin does not disrupt
p53
-
MDMX
interaction. The ability of Nutlin to activate
p53
is compromised in tumor cells overexpressing
MDMX
. Combination of Nutlin with
MDMX
siRNA resulted in synergistic activation of
p53
and growth arrest. These results suggest that
MDMX
is also a valid target for
p53
activation in tumor cells. Development of novel compounds that are
MDMX
-specific or optimized for dual-inhibition of MDM2 and
MDMX
are necessary to achieve full activation of
p53
in tumor cells.
...
PMID:MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. 1690 41
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>